Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;202(3):498-503.
doi: 10.1111/bjh.18894. Epub 2023 Jun 12.

Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes

Justin Loke  1   2   3 , Vinit Upasani  4 , Charlotte Gaskell  2 , Sonia Fox  2 , Rachel Fletcher  2 , Catherine Thomas  2 , Louise Hopkins  2 , Anita Kumari  2 , Tina Tang  2 , Emily Yafai  2 , Rebecca Boucher  2 , Victoria Homer  2 , Arpad Toth  5 , Y L Tracey Chan  6 , Katie Randall  7 , Tom Rider  8 , Jenny O'Nions  9 , Victoria Drew  10 , Arvind Pillai  11 , Moez Dungarwalla  12 , Duncan Murray  13 , Anjum Khan  14 , Farooq Wandroo  15 , Sally Moore  16 , Pramila Krishnamurthy  17 , Ya-Wen Jessica Huang  18 , Steve Knapper  19 , Jenny Byrne  20 , Rui Zhao  21 , Charles Craddock  1   2 , Helen Parry  1   22 , Paul Moss  1   22 , Simon J Stanworth  23   24   25 , David M Lowe  4   26
Affiliations

Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes

Justin Loke et al. Br J Haematol. 2023 Aug.

Abstract

Limited data exist on COVID-19 vaccination efficacy in patients with acute myeloid leukemia and myelodysplasia with excess blasts (AML/MDS-EB2). We report results from a prospective study, PACE (Patients with AML and COVID-19 Epidemiology). 93 patients provided samples post-vaccine 2 or 3 (PV2, PV3). Antibodies against SARS-COV-2 spike antigen were detectable in all samples. Neutralization of the omicron variant was poorer than ancestral variants but improved PV3. In contrast, adequate T-cell reactivity to SARS-COV-2 spike protein was seen in only 16/47 (34%) patients PV2 and 23/52 (44%) PV3. Using regression models, disease response (not in CR/Cri), and increasing age predicted poor T cell response.

Keywords: AML; COVID; MDS; vaccination.

PubMed Disclaimer

References

REFERENCES

    1. Lee LYW, Cazier J-B, Starkey T, Briggs SEW, Arnold R, Bisht V, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21(10):1309-16.
    1. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.
    1. Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021;39(8):1031-3.
    1. Loke J, Malladi R, Moss P, Craddock C. The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. Br J Haematol. 2020;188(1):129-46.
    1. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345-77.

Publication types

Supplementary concepts

Associated data